MANKINDNSEMankind Pharma Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 6 Nov, 2025 · 16:44 IST

FY26 half-year revenue rises 23%, but net profit falls 20%; tax cases continue

Emphasis Of MatterRevenue Growth 20pctEbitda Margin CompressionResults RestatedResults View source PDFExplain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.8%Reaction day
₹2310.00
prior close
₹2250.00
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.5%-2.3% vs market
Pharmaceuticals peers, median of 156sector-0.0%-1.8% vs sector

On the reaction day the stock moved 2.3 pts less than Nifty Midcap 150 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.7
10m
+0.8
15m
+0.9
30m
+1.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.8+0.5-2.3-0.0-1.8
Next day
-3.1+0.9-4.0-0.7-2.4
2d
-3.9+1.4-5.3-0.9-3.0
3d
-1.1+2.1-3.2+0.1-1.2
4d
-2.0+1.8-3.8+0.2-2.2
5d
-1.6+1.9-3.5+0.0-1.6
1w
-3.7+1.9-5.6-0.3-3.4
15d
-2.6+2.2-4.7-1.6-0.9
1m
-5.3-0.4-4.9-5.3+0.0
2m
-0.2+3.1-3.3-2.9+2.7
3m
-9.8+1.6-11.4-7.3-2.5
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the six months, consolidated revenue rose 22.6% to Rs 7,267.51 crore, but net profit fell 19.6% to Rs 964.80 crore. Q2 revenue was Rs 3,697.16 crore, up 20.8%, while net profit fell 21.3% to Rs 520.18 crore. Standalone operating margin dropped to 27% from 30%. Auditors highlighted tax cases involving disputed adjustments of about Rs 1,825.66 crore. Earlier figures were restated for three merged subsidiaries.

Likely market impact

Revenue growth helps, but falling profit and unresolved tax cases may pressure the stock and raise volatility.